icon-folder.gif   Conference Reports for NATAP  
 
  64rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Washington, DC Nov 1-5 2013
Back grey_arrow_rt.gif
 
 
 
Comparison of the overall survival between patients with HCV-induced advanced hepatic fibrosis and the general population
 
 
  Reported by Jules Levin
 
AASLD Nov 2013 - the 64th Annual Meeting of the American Association for the Study of Liver Diseases, November 1 - November 5 2013, Washington, DC, USA.
 
Adriaan J.P. van der Meer1, Bettina E. Hansen1, Jordan J. Feld2, Heiner Wedemeyer3, Jean-FranÁois Dufour4, Frank Lammert5, Andres Duarte-Rojo2, Michael P. Manns3, Stefan Zeuzem6, W. Peter Hofmann6, Robert J. de Knegt1, Bart J. Veldt1 and Harry L.A. Janssen1,2
 
1Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands; 2Liver centre, Toronto Western hospital, University Health Network, Toronto, Ontario, Canada; 3Department of Gastroenterology, Hepatology, and Endocrinology, Medical School Hannover, Hannover, Germany; 4Institute of Clinical Pharmacology, University of Bern, Bern, Switserland; 5Department of Medicine II, Saarland University Medical Center, Homburg, Germany; 6Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe-Universitšt, Frankfurt am Main, Germany

AASLD1.gif

Online: www.erasmusmc.nl and www.liver-gi.nl
 
Conclusion
 
Among patients with HCV-induced advanced hepatic fibrosis or cirrhosis SVR was associated with reduced all-cause mortality, the most definite clinical endpoint.
 
Despite established advanced liver disease, those patients with chronic HCV infection who attained SVR showed a comparable survival to that of the general Dutch population.
 
This further supports SVR is a relevant surrogate endpoint of anti-HCV therapy.
 
"randomized controlled trials showing a clinical benefit of antiviral therapy and validating SVR as surrogate endpoint are lacking. Therefore, studies suggesting clinical benefit of SVR are important to justify intensive and costly antiviral therapy or implementation of HCV screening programs.
 
We aimed to compare the overall survival of patients with HCV-induced advanced hepatic fibrosis or cirrhosis, with and without SVR, to that of the general Dutch population"

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif